Results 301 to 310 of about 203,911 (336)

Early Ki67 change predicts prognosis and supports response-adapted therapy in breast cancer treated with neoadjuvant chemotherapy. [PDF]

Breast
Zhang Y, Wu S, Xue L, Xie Y, Shen J, Shao Z, Liu G.   +6 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Ki67 targeted strategies for cancer therapy

Clinical and Translational Oncology, 2018
Ki67 is a well-known proliferation marker for the evaluation of cell proliferation. Numerous studies have indicated that Ki67 index independently predicts cancer progression. Moreover, because Ki67 is highly expressed in malignant cells but almost could not be detected in normal cells, it has become a promising target for cancer therapy. In this review,
C. Yang, J. Zhang, M. Ding, K. Xu, Liantao Li, Lijun Mao, Junnian Zheng   +6 more
semanticscholar   +3 more sources

Ki67 and Salivary Cancer

Cancer Investigation, 2008
We examined Ki67 expression in salivary malignancies of 75 patients with a follow-up period of up to 20 years. Correlations between enhanced Ki67 and enhanced p53 and TUNEL and heparanase staining levels were significant. Median survival for reduced-stained-tumor patients (< or = 5%) was 163 months, dropping significantly to 39 months (p = 0.0005) for ...
Ofer, Ben-Izhak, Sharon, Akrish, Rafael M, Nagler   +2 more
openaire   +2 more sources

Ki67 as Proliferative Marker in Patients with Early Breast Cancer and Its Association with Clinicopathological Factors

Oncology, 2021
Introduction: Ki67 as a proliferative marker has prognostic and therapeutic relevance in early breast cancer (EBC). However, standard cutoffs for distinguishing low and high Ki67 do not exist.
Amelie de Gregorio, T. Friedl, Eva Hering, P. Widschwendter, N. de Gregorio, I. Bekes, W. Janni, D. Dayan, J. Huober   +8 more
semanticscholar   +1 more source

Improving Ki67 assessment concordance by the use of an artificial intelligence‐empowered microscope: a multi‐institutional ring study

Histopathology, 2021
The nuclear proliferation biomarker Ki67 plays potential prognostic and predictive roles in breast cancer treatment. However, the lack of interpathologist consistency in Ki67 assessment limits the clinical use of Ki67.
Lijing Cai, Kezhou Yan, H. Bu, M. Yue, Pei Dong, Xinran Wang, Lina Li, Kuan Tian, Haocheng Shen, Jun Zhang, J. Shang, Shuyao Niu, Dandan Han, Chen Ren, Junzhou Huang, Xiao Han, Jianhua Yao, Yueping Liu   +17 more
semanticscholar   +1 more source

A simple digital image analysis system for automated Ki67 assessment in primary breast cancer

Histopathology, 2021
Ki67 is a well‐established immunohistochemical marker associated with cell proliferation that has prognostic and predictive value in breast cancer. Quantitative evaluation of Ki67 is traditionally performed by assessing stained tissue slides with light ...
Anastasia Alataki, L. Zabaglo, H. Tovey, A. Dodson, M. Dowsett   +4 more
semanticscholar   +1 more source

Ki67 protein: the immaculate deception?

Histopathology, 2002
Ki67 protein: the immaculate deception? This article updates our previous review of Ki67 published in Histopathology 10 years ago. In this period the numbers of papers published featuring this antibody has increased 10‐fold from 338 to 3489 indicating the considerable enthusiasm with which this antibody has been studied.
D C, Brown, K C, Gatter
openaire   +3 more sources

Ki67 and proliferation in breast cancer

Journal of Clinical Pathology, 2013
New approaches to the prognostic assessment of breast cancer have come from molecular profiling studies. A major feature of this work has been to emphasise the importance of cancer cell proliferation as a key discriminative indicator of recurrence risk for oestrogen receptor positive breast cancer in particular. Mitotic count scoring, as a component of
Nirmala, Pathmanathan, Rosemary L, Balleine   +1 more
openaire   +2 more sources

P53 and Ki67 in Adrenocortical Tumors

Endocrine Research, 2000
The p53 tumor-supressor gene has been reported as the most frequent genetic abnormality seen in human malignancies. Here we studied immunohistochemically the expression of p53 in a large series of adrenocortical tumors. The proliferative activity was assessed by the expression of Ki67.
J, Arola, K, Salmenkivi, J, Liu, A I, Kahri, P, Heikkilä   +4 more
openaire   +2 more sources